Home
Live Updates
Adding Chemotherapy to Osimertinib Improves PFS in EGFR-Mutant, Advanced NSCLC : comparemela.com
Adding Chemotherapy to Osimertinib Improves PFS in EGFR-Mutant, Advanced NSCLC
Osimertinib and chemotherapy is more effective than osimertinib alone as first-line treatment for EGFR-mutant, advanced NSCLC, phase 3 data suggest.
Related Keywords
Boston ,
Massachusetts ,
United States ,
Dana Farber Cancer Institute ,
Daiichi Sankyo ,
Eli Lilly ,
Roche Genentech ,
Astellas Pharmaceuticals ,
Gatekeeper Pharmaceuticals ,
Boehringer Ingelheim ,
Pfizer ,
Novartis ,
Astrazeneca ,
Chugai Pharmaceuticals ,
Pasi Janne ,
Mirati Therapeutics ,
Revolution Medicines ,
Silicon Therapeutics ,
Takeda Oncology ,
comparemela.com © 2020. All Rights Reserved.